Two Struggling Stocks Poised for a Potential Comeback
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 03 2025
0mins
Source: NASDAQ.COM
Novo Nordisk's Growth Potential: Novo Nordisk has several upcoming catalysts, including late-stage studies for CagriSema and a potential oral semaglutide formulation, which could significantly boost its revenue and market position.
Regeneron's Resilience: Despite facing biosimilar competition for Eylea, Regeneron has shown strong financial results, with a 1% revenue growth and promising developments in its product pipeline, including Dupixent and a new cancer therapy, Lynozyfic.
Investment Opportunities: Both Novo Nordisk and Regeneron are considered attractive investment options due to their potential for recovery and growth, especially as Novo Nordisk's stock is currently undervalued.
Stock Advisor Recommendations: The Motley Fool's Stock Advisor has identified other stocks as top picks, suggesting that while Novo Nordisk is recommended, it did not make the top 10 list, which has historically yielded significant returns for investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 43.550
Low
42.00
Averages
54.67
High
70.00
Current: 43.550
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novo Nordisk to File for Wegovy Approval in China Soon
- Market Expansion Plans: Novo Nordisk's CEO Mike Doustdar announced that the company will submit its Wegovy weight-loss pill for regulatory approval in China within a few months, indicating its intent to expand in the world's second-largest market and compete with Eli Lilly's orforglipron.
- Product Launch Context: Wegovy was launched in the U.S. earlier this year after receiving FDA approval in December, and Novo Nordisk aims to mitigate potential impacts on its GLP-1 franchise from the upcoming patent expiry of semaglutide, the active ingredient in its diabetes therapies, by introducing Wegovy in China.
- Competitive Advantage Analysis: Doustdar noted that one barrier to entry for Wegovy will be the scaling of production capabilities, suggesting that not many competitors will have the necessary capacity, which could provide Novo Nordisk with a strategic edge in the Chinese market.
- Industry Dynamics Observation: Eli Lilly submitted its marketing application for its oral GLP-1 therapy orforglipron to Chinese regulators at the end of last year, highlighting the intensifying competition in this sector, and Novo Nordisk's timely application will help position it effectively in the market.
See More
FDA Issues Warning Letters to Telehealth Firms Over Misleading GLP-1 Claims
- Warning Letter Count: The FDA has issued 25 warning letters to telehealth firms for allegedly making false claims about low-cost compounded GLP-1 drugs, indicating the regulator's stringent oversight of the market.
- Product Safety Concerns: The FDA emphasized that these compounded drugs have not been proven safe or effective compared to FDA-approved GLP-1 medications from Novo Nordisk (NVO) and Eli Lilly (LLY), posing potential health risks to consumers and highlighting the importance of consumer protection.
- Market Reaction: Compounded GLP-1 drugs surged in popularity due to shortages of branded medications, with the FDA sending over 100 warning letters to telehealth firms, including Hims & Hers (HIMS), demonstrating a zero-tolerance approach to misleading marketing.
- Industry Impact: Following a deal with Novo Nordisk, HIMS ceased marketing its compounded GLP-1 drugs in favor of branded options, reflecting a growing emphasis on compliance and consumer trust, which may influence future market strategies.
See More
Analysis of Weight Loss Drug Market Prospects
- Market Growth Potential: Analysts project rapid growth in the weight loss market over the coming years, with Eli Lilly and Novo Nordisk as industry leaders, showing a stark contrast in performance with Eli Lilly's 40% stock increase and Novo Nordisk's 42% decline over the past year, highlighting intense market competition.
- Eli Lilly's Advantages: Eli Lilly's weight loss drug Zepbound is currently the best-seller in this niche, with Q1 revenue soaring 56% year-over-year to $19.8 billion and EPS skyrocketing 170% to $8.26, underscoring its strong market position in chronic weight management.
- Novo Nordisk's Catch-Up: Novo Nordisk's oral GLP-1 drug Wegovy has achieved over two million prescriptions in Q1, and while facing competitive pressure from Eli Lilly, the approval of a high-dose Wegovy formulation could enhance its competitive edge.
- Investment Value Comparison: Although Novo Nordisk's forward P/E of 13 appears more attractive than Eli Lilly's 31.3, Eli Lilly's dominance in the weight loss sector and diversified portfolio make it a more compelling investment choice at this time.
See More
Eli Lilly and Novo Nordisk Compete in Weight Loss Market
- Market Leadership: Eli Lilly leads the weight loss market with a remarkable 56% year-over-year revenue increase to $19.8 billion in Q1, while its EPS soared 170% to $8.26, showcasing its strong performance in chronic weight management and solidifying its market share.
- Product Line Expansion: Eli Lilly's weight loss drug Zepbound has become the best-seller in this niche, and the newly approved oral GLP-1 therapy Foundayo is attracting patients hesitant about injectable drugs, which is expected to expand its addressable market and enhance its customer base.
- Changing Competitive Dynamics: Novo Nordisk is regaining competitiveness in the weight loss market, with its oral Wegovy achieving over two million prescriptions since launch, and the newly approved high-dose Wegovy is likely to enhance its market share, helping it compete with Eli Lilly's Zepbound.
- Future Potential: Although Novo Nordisk's forward P/E of 13 appears more attractive than Eli Lilly's 31.3, Eli Lilly is still viewed as the more valuable investment due to its diversified product portfolio and dominant position in the weight loss sector.
See More
Markets Pause as Investors Assess Latest Rally Amid Fed Meeting
- Market Rally Assessment: Markets are taking a breather as investors reassess the recent rally driven by easing tensions in the Middle East, particularly ahead of the Federal Reserve's first policy meeting under Chair Kevin Warsh, where interest rates are expected to remain steady, reflecting cautious sentiment regarding future policy directions.
- SpaceX Stock Frenzy: SpaceX shares crossed a $2.5 trillion valuation on Monday, although Wall Street analysts are raising concerns about high valuations, especially as veteran short-seller Jim Chanos warns that investors rarely profit from buying companies valued at more than 100 times revenue, which may impact retail investor confidence.
- Novo Nordisk's China Plans: Novo Nordisk announced plans to seek regulatory approval for its oral Wegovy weight-loss pill in China within the next few months, aiming to challenge Eli Lilly's market position, indicating its strategic intent to expand in the Chinese market.
- Economic Data Focus: Investors are closely tracking the upcoming release of the U.S. ADP weekly employment change and housing starts data, which will provide further directional guidance for the market, especially in the context of the Federal Reserve's policy decisions.
See More
Three Innovative Biotechs with Promising Prospects
- Madrigal Approval: Madrigal Pharmaceuticals made history in 2024 by earning approval for Rezdiffra, the first treatment for metabolic dysfunction-associated steatohepatitis, addressing the urgent needs of millions of patients in the U.S., and is expected to see significant revenue growth over the next decade.
- Axsome Sales Surge: Axsome Therapeutics reported first-quarter sales of $153.2 million for its Auvelity drug, a 59% year-over-year increase, and has received label expansion for treating Alzheimer's disease agitation, projecting peak sales of $8 billion in the future.
- Kailera's Market Potential: Kailera Therapeutics focuses on developing weight loss medications and, despite not having marketed products, its leading candidate ribupatide is currently in phase 3 trials, potentially positioning it well in the rapidly growing anti-obesity market.
- Investment Risks and Opportunities: While Madrigal and Axsome face competition and regulatory risks, their market prospects and pipeline potential make them attractive for investors, particularly for those looking at long-term investments in the biotech sector.
See More
Novo Nordisk to File for Wegovy Approval in China Soon
- Market Expansion Plans: Novo Nordisk's CEO Mike Doustdar announced that the company will submit its Wegovy weight-loss pill for regulatory approval in China within a few months, indicating its intent to expand in the world's second-largest market and compete with Eli Lilly's orforglipron.
- Product Launch Context: Wegovy was launched in the U.S. earlier this year after receiving FDA approval in December, and Novo Nordisk aims to mitigate potential impacts on its GLP-1 franchise from the upcoming patent expiry of semaglutide, the active ingredient in its diabetes therapies, by introducing Wegovy in China.
- Competitive Advantage Analysis: Doustdar noted that one barrier to entry for Wegovy will be the scaling of production capabilities, suggesting that not many competitors will have the necessary capacity, which could provide Novo Nordisk with a strategic edge in the Chinese market.
- Industry Dynamics Observation: Eli Lilly submitted its marketing application for its oral GLP-1 therapy orforglipron to Chinese regulators at the end of last year, highlighting the intensifying competition in this sector, and Novo Nordisk's timely application will help position it effectively in the market.
See More
FDA Issues Warning Letters to Telehealth Firms Over Misleading GLP-1 Claims
- Warning Letter Count: The FDA has issued 25 warning letters to telehealth firms for allegedly making false claims about low-cost compounded GLP-1 drugs, indicating the regulator's stringent oversight of the market.
- Product Safety Concerns: The FDA emphasized that these compounded drugs have not been proven safe or effective compared to FDA-approved GLP-1 medications from Novo Nordisk (NVO) and Eli Lilly (LLY), posing potential health risks to consumers and highlighting the importance of consumer protection.
- Market Reaction: Compounded GLP-1 drugs surged in popularity due to shortages of branded medications, with the FDA sending over 100 warning letters to telehealth firms, including Hims & Hers (HIMS), demonstrating a zero-tolerance approach to misleading marketing.
- Industry Impact: Following a deal with Novo Nordisk, HIMS ceased marketing its compounded GLP-1 drugs in favor of branded options, reflecting a growing emphasis on compliance and consumer trust, which may influence future market strategies.
See More
Analysis of Weight Loss Drug Market Prospects
- Market Growth Potential: Analysts project rapid growth in the weight loss market over the coming years, with Eli Lilly and Novo Nordisk as industry leaders, showing a stark contrast in performance with Eli Lilly's 40% stock increase and Novo Nordisk's 42% decline over the past year, highlighting intense market competition.
- Eli Lilly's Advantages: Eli Lilly's weight loss drug Zepbound is currently the best-seller in this niche, with Q1 revenue soaring 56% year-over-year to $19.8 billion and EPS skyrocketing 170% to $8.26, underscoring its strong market position in chronic weight management.
- Novo Nordisk's Catch-Up: Novo Nordisk's oral GLP-1 drug Wegovy has achieved over two million prescriptions in Q1, and while facing competitive pressure from Eli Lilly, the approval of a high-dose Wegovy formulation could enhance its competitive edge.
- Investment Value Comparison: Although Novo Nordisk's forward P/E of 13 appears more attractive than Eli Lilly's 31.3, Eli Lilly's dominance in the weight loss sector and diversified portfolio make it a more compelling investment choice at this time.
See More
Eli Lilly and Novo Nordisk Compete in Weight Loss Market
- Market Leadership: Eli Lilly leads the weight loss market with a remarkable 56% year-over-year revenue increase to $19.8 billion in Q1, while its EPS soared 170% to $8.26, showcasing its strong performance in chronic weight management and solidifying its market share.
- Product Line Expansion: Eli Lilly's weight loss drug Zepbound has become the best-seller in this niche, and the newly approved oral GLP-1 therapy Foundayo is attracting patients hesitant about injectable drugs, which is expected to expand its addressable market and enhance its customer base.
- Changing Competitive Dynamics: Novo Nordisk is regaining competitiveness in the weight loss market, with its oral Wegovy achieving over two million prescriptions since launch, and the newly approved high-dose Wegovy is likely to enhance its market share, helping it compete with Eli Lilly's Zepbound.
- Future Potential: Although Novo Nordisk's forward P/E of 13 appears more attractive than Eli Lilly's 31.3, Eli Lilly is still viewed as the more valuable investment due to its diversified product portfolio and dominant position in the weight loss sector.
See More
Markets Pause as Investors Assess Latest Rally Amid Fed Meeting
- Market Rally Assessment: Markets are taking a breather as investors reassess the recent rally driven by easing tensions in the Middle East, particularly ahead of the Federal Reserve's first policy meeting under Chair Kevin Warsh, where interest rates are expected to remain steady, reflecting cautious sentiment regarding future policy directions.
- SpaceX Stock Frenzy: SpaceX shares crossed a $2.5 trillion valuation on Monday, although Wall Street analysts are raising concerns about high valuations, especially as veteran short-seller Jim Chanos warns that investors rarely profit from buying companies valued at more than 100 times revenue, which may impact retail investor confidence.
- Novo Nordisk's China Plans: Novo Nordisk announced plans to seek regulatory approval for its oral Wegovy weight-loss pill in China within the next few months, aiming to challenge Eli Lilly's market position, indicating its strategic intent to expand in the Chinese market.
- Economic Data Focus: Investors are closely tracking the upcoming release of the U.S. ADP weekly employment change and housing starts data, which will provide further directional guidance for the market, especially in the context of the Federal Reserve's policy decisions.
See More
Three Innovative Biotechs with Promising Prospects
- Madrigal Approval: Madrigal Pharmaceuticals made history in 2024 by earning approval for Rezdiffra, the first treatment for metabolic dysfunction-associated steatohepatitis, addressing the urgent needs of millions of patients in the U.S., and is expected to see significant revenue growth over the next decade.
- Axsome Sales Surge: Axsome Therapeutics reported first-quarter sales of $153.2 million for its Auvelity drug, a 59% year-over-year increase, and has received label expansion for treating Alzheimer's disease agitation, projecting peak sales of $8 billion in the future.
- Kailera's Market Potential: Kailera Therapeutics focuses on developing weight loss medications and, despite not having marketed products, its leading candidate ribupatide is currently in phase 3 trials, potentially positioning it well in the rapidly growing anti-obesity market.
- Investment Risks and Opportunities: While Madrigal and Axsome face competition and regulatory risks, their market prospects and pipeline potential make them attractive for investors, particularly for those looking at long-term investments in the biotech sector.
See More
